Want to see SE:PAX full AI Analyst Report?
PAX Stock Chart & Stats
kr46.75
kr0.40(0.86%)
At close: 4:00 PM EDT
kr46.75
kr0.40(0.86%)
Day’s Range― - ―
52-Week Rangekr41.00 - kr82.60
Previous CloseN/A
Volume1.85K
Average Volume (3M)100.37K
Market Cap
kr1.12B
Enterprise Valuekr1.08B
Total Cash (Recent Filing)kr106.09M
Total Debt (Recent Filing)kr4.58M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 21, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding23,273,417
10 Day Avg. Volume41,338
30 Day Avg. Volume100,373
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-76.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.91
Revenue Forecast (FY)kr412.65M
Bulls Say, Bears Say
Bulls Say
Solid Revenue GrowthConsistent, high single- to double-digit revenue growth (Fundamentals.RevenueGrowth ~28%) supports a growing installed base and rising consumable and service usage per site. Durable top-line expansion strengthens recurring revenues, yields scale economics and funds continued clinical adoption over multiple quarters.
Conservative, Low-leverage Balance SheetA very low debt load (debt/equity ~0.03) gives Paxman strong financial flexibility to fund device placements, training and distributor support while absorbing temporary losses without material refinancing risk. Conservative capitalization supports multi-quarter commercialization and R&D investment.
Recurring Revenue And Distribution ModelPaxman's mix of capital equipment placements plus recurring consumables, per-treatment fees and service contracts, together with distributor arrangements, generates annuity-like revenue from installed systems. This structure supports durable, scalable revenue and lowers dependence on one-off device sales over time.
Bears Say
Deteriorating ProfitabilityThe transition to net losses in 2025 and TTM demonstrates margin deterioration and weak profitability conversion. Prolonged unprofitability erodes retained earnings, constrains reinvestment capacity and forces management to restore utilization, pricing or cost controls to sustainably return to profitable operations.
Weak Cash GenerationNegative operating cash flow in the TTM and negative free cash flow in 2025 and TTM indicate inconsistent cash generation and potential cash burn. This limits funding for capex, working capital and international rollout, increasing reliance on external financing if the trend persists and stressing multi-quarter execution.
Negative Returns On EquityROE turning negative in 2025 and TTM shows the company is not generating returns on shareholders' capital. Persistent negative ROE undermines internal funding for growth, may raise the cost of capital, and could pressure management to change capital allocation or seek dilutive external capital to sustain expansion.
Paxman AB News
PAX FAQ
What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was kr41.00 and its highest was kr82.60 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is kr1.12B.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s upcoming earnings report date is Aug 21, 2026 which is in 19 days.
How were Paxman AB’s earnings last quarter?
Paxman AB released its earnings results on May 21, 2026. The company reported kr0 earnings per share for the quarter, missing the consensus estimate of kr0.1 by -kr0.1.
Is Paxman AB overvalued?
According to Wall Street analysts Paxman AB’s price is currently Overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate is 0.4.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Paxman AB reported an EPS of kr0 in its last earnings report, missing expectations of kr0.1. Following the earnings report the stock price went up 0.1%.
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in SE:PAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Paxman AB
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, various Asian regions, and both South and Central America, primarily serving cancer centers and hospitals. The company is also engaged in a research collaboration agreement with the National University Hospital in Singapore, working towards the development of a portable cooling and compression device. Established in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.
PAX Earnings Call
Q1 2026
0:00 / 0:00